We usually frame HA molecular weight distribution around the idea of maintaining HMW-HA homeostasis. The standard model suggests that aging triggers overactive hyaluronidases, which then churn out pro-inflammatory LMW-HA fragments capable of activating TLR2/4 signaling. But I’m beginning to think we have the causality backward.

What if the real problem isn't excessive enzymatic breakdown, but a breakdown in HAS2-mediated synthetic buffering?

In both the dermis and synovial fluid, we observe a distinct collapse in HA turnover kinetics. If HAS2 expression plummets—as is common in aged dermal fibroblasts—the tissue loses its capacity to "dilute" the spontaneous oxidative cleavage that happens over time. It’s not necessarily that hyaluronidases have gone rogue; rather, the system can't replace long-chain polymers fast enough to keep the fragment-to-polymer ratio below the threshold for DAMP-mediated inflammation.

If that’s the case, our current efforts to inhibit hyaluronidases might be hitting the wrong target. The real challenge may be restoring the high-flux synthesis of HMW-HA.

I’ve been stuck on a few specific questions:

• How can we reliably distinguish between accidental oxidative fragmentation and regulated hyaluronidase activity in vivo?
• Is there a specific threshold of HAS2 activity required to suppress inflammatory signaling, irrespective of hyaluronidase levels?
• Why do some tissues manage to preserve HMW-HA integrity well into old age while others lose it so quickly?

I’m curious if anyone has seen evidence that HAS2 supplementation or transcriptional reactivation can actually dampen pro-inflammatory signaling initiated by existing LMW-HA, or if the fragment feedback loop remains self-sustaining even when synthesis is restored. I'd love to hear your thoughts on these mechanics.